All Stories

  1. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance

    Article • Journal of Medical Economics, September 2019, Taylor & Francis

    Matthew Borrego, Prof dr Ivo Abraham

  2. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma

    Article • Journal of Medical Economics, September 2019, Taylor & Francis

    Prof dr Ivo Abraham

  3. Why health policies should be transnational: A case for East Asia Pacific countries

    Article • International Journal of Risk & Safety in Medicine, July 2019, IOS Press

    Prof dr Ivo Abraham

  4. Real-World Evidence from the Integrative Medicine Primary Care Trial (IMPACT): Assessing Patient-Reported Outcomes at Baseline and 12-Month Follow-Up

    Article • Evidence-based Complementary and Alternative Medicine, June 2019, Hindawi Publishing Corporation

    Prof dr Ivo Abraham

  5. A Cautionary Research Note on Standard Versus Extended Release Tacrolimus

    Article • Progress in Transplantation, December 2018, SAGE Publications

    Prof dr Ivo Abraham

  6. Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study

    Article • Journal of Medical Economics, October 2018, Taylor & Francis

    Prof dr Ivo Abraham

  7. Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure

    Article • Expert Review of Precision Medicine and Drug Development, September 2018, Taylor & Francis

    Prof dr Ivo Abraham

  8. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence

    Article • Expert Opinion on Biological Therapy, February 2018, Taylor & Francis

    Prof dr Ivo Abraham

  9. Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study

    Article • Patient Preference and Adherence, October 2017, Dove Medical Press

    Prof dr Ivo Abraham, Andrea Zimmer

  10. Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients

    Article • International Journal of Chronic Diseases, January 2017, Hindawi Publishing Corporation

    Prof dr Ivo Abraham

  11. Detectability and acceptability of continuous pulse signals for the MemoPatch® device, an electronic skin patch intended to deliver tactile medication reminder signals

    Article • Medical Devices Evidence and Research, February 2015, Taylor & Francis

    Prof dr Ivo Abraham

  12. Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study)

    Article • European Journal of Cancer Care, October 2013, Wiley

    Prof dr Ivo Abraham

  13. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study

    Article • Clinical Ophthalmology, September 2013, Taylor & Francis

    Prof dr Ivo Abraham

  14. "Later, lazier, and unluckier”: a heuristic profile of high vulnerability is an independent predictor of uncontrolled blood pressure (the PREVIEW study)

    Article • International Journal of General Medicine, June 2010, Taylor & Francis

    Prof dr Ivo Abraham